Oculis AG (OCS): Forward Price-to-Revenue Multiple

Oculis (OCS) - corporate logo

Oaktree Specialty Lending (OCS) minimizes risks by lending to a resilient private sector across various niches. The forward price-to-sales valuation trend captures this process, with the metric reaching 2547.20. Growth is driven by the creation of a closed-loop treatment cycle via innovative drug delivery platforms. A strong team of biochemists, retained through lucrative stock options, ensures the stability of the system.

OCS Oculis: Forward Price to Sales in the range 04/28/2023 - 12/03/2024

OCS (Oculis): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Oculis AG|OCS - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Valuation Oculis Pharma|OCS - Aggregate Business Value
- business book valuation details:
Net Assets per Single Share Oculis|OCS - Accounting Value of Company|Market Capitalization to Book Value Ratio oculis.com|OCS - Company Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Oaktree Specialty Lending|OCS - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio oculis.com|OCS - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Oculis AG|OCS - Long-Term Debt Volume|Company Short-Term Debt Oculis|Quick Ratio oculis.com
- business earnings and investment ratios data:
OCS - Company Net Income|Projected Future Earnings Oaktree Specialty Lending|OCS - Price to Earnings Ratio|Forward P/E Multiple Oculis AG|OCS - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Oculis|OCS - Operating profit EBITDA|Earnings per share for the last twelve months Oculis|OCS - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months oculis.com|OCS - Net earnings per one share growth for the current year|Expected earnings per share growth for next year Oaktree Specialty Lending
- company sales and revenue statistics:
OCS - Company Total Revenue|Company Future Sales Volume Oaktree Specialty Lending|OCS - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio Oculis Holding AG|OCS - Sales Growth YoY (Last Twelve Months)
Summary company analysis:OCS (Oculis Holding)
Product sample of oculis.com

Management's authority in the ophthalmology sector ensures high business resilience for Oaktree Specialty Lending (OCS). The forward P/S ratio correlates current market capitalization with expected revenue, allowing for an assessment of capital management efficiency between reporting periods. An increase in this metric signals inflated market expectations regarding future sales, while a downward trend in the forward P/S curve indicates that assets are undervalued relative to their fundamental productivity.

Analysis of competing companies

Forward P/S Multiple ALC (Alcon Corp)|Forward P/S Multiple Bausch + Lomb Corporation BLCO|Glaukos Medical - Forward P/S Multiple|Market Cap to Future Revenue Ratio apellis.com|BLTE: Forward P/S Multiple|OCUL (Ocular Therapeutix, Inc.) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio harrowinc.com|Market Cap to Projected Revenue VRDN (Viridian Pharma)|Forward Price-to-Revenue Multiple LENZ (LENZ Pharma)|Market Cap to Expected Sales Ratio eyepointpharma.com|Price-to-Projected Revenue Ratio Kodiak Sciences Inc KOD|Forward P/S Multiple aldeyra.com ALDX|KALA - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Opus Genetics, Inc.|OKYO Pharma Inc (OKYO) - Price-to-Projected Revenue Ratio|ADVM (Adverum Biotechnologies Inc.) - Price-to-Projected Revenue Ratio|OTLK (Outlook Therapeutics, Inc.) - Forward P/S Multiple|CLSD: Forward Price to Sales|Price-to-Projected Revenue Ratio NovaBay Pharmaceuticals Inc. (NBY)|Forward Price-to-Revenue Multiple Kiora Pharmaceuticals, Inc. KPRX|Forward P/S Multiple ALIM (Alimera Sciences, Inc.)|EYEN - Forward Price-to-Revenue Multiple|GHSI - Price-to-Projected Revenue Ratio|Forward Price to Sales OCUP (Ocuphire Pharma Inc)|opthea.com (OPT) - Price-to-Projected Revenue Ratio